LYFCX Mutual Fund (AlphaCentric Life Sciences and Healthcare Fund Class C) is managed by Alpha Centric Fund with $2.1M in net assets. LYFCX expense ratio is 2.46%, holding 63 positions across sectors including Health Care, Unknown, Financials. Inception date: 2019-11-29.

LYFCX performance shows a YTD return of 17.53%. The 1-year return is 53.23% and the 5-year return is 6.19%. LYFCX dividend yield stands at 0.63%, paid annually.

LYFCX top holdings include First Am Treas Obli-X (7.7%), Gilead Sciences Inc (7.2%), Astrazeneca Plc (5.6%), Nvaesrtex Pharmaceuticals Inc (5.6%), Ionis Pharmaceuticals Inc (3.7%). View all LYFCX holdings, sector breakdown, or dividend history.

LYFCX can be compared against other funds using the overlap calculator or side-by-side comparison tool. LYFCX alternatives are available via the screener, along with tax-loss harvesting opportunities.